Shenzhen Chipscreen Biosciences Yönetim

Yönetim kriter kontrolleri 2/4

Shenzhen Chipscreen Biosciences CEO'su Xian-Ping Lu, Jan2001 tarihinde atandı, in görev süresi 23.83 yıldır. şirketin hisselerinin 5.45% doğrudan sahiptir ve bu hisselerin değeri CN¥ 478.82M dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 15.3 yıl ve 6.7 yıldır.

Anahtar bilgiler

Xian-Ping Lu

İcra Kurulu Başkanı

CN¥3.4m

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	23.8yrs
CEO sahipliği	5.5%
Yönetim ortalama görev süresi	15.3yrs
Yönetim Kurulu ortalama görev süresi	6.7yrs

Son yönetim güncellemeleri

Recent updates

Shenzhen Chipscreen Biosciences Co., Ltd.'s (SHSE:688321) 50% Price Boost Is Out Of Tune With Revenues

Oct 08

Shenzhen Chipscreen Biosciences Co., Ltd.'s (SHSE:688321) Price In Tune With Revenues

Aug 21

We Think Shenzhen Chipscreen Biosciences (SHSE:688321) Has A Fair Chunk Of Debt

Jun 04

Investors Appear Satisfied With Shenzhen Chipscreen Biosciences Co., Ltd.'s (SHSE:688321) Prospects As Shares Rocket 26%

Apr 24

Solid Earnings May Not Tell The Whole Story For Shenzhen Chipscreen Biosciences (SHSE:688321)

Apr 05

Shenzhen Chipscreen Biosciences Co., Ltd.'s (SHSE:688321) Shares Climb 30% But Its Business Is Yet to Catch Up

Mar 06

CEO

Xian-Ping Lu (60 yo)

23.8yrs

Görev süresi

CN¥3,384,700

Tazminat

Dr. Xian-Ping Lu Founded Shenzhen Chipscreen Biosciences Ltd. in 2001 and has been its Chairman since March 2018. Dr. Lu has been Chief Executive Officer, General Manager and President of Shenzhen Chipscre...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Xian-Ping Lu	Founder	23.8yrs	CN¥3.38m	5.45% CN¥ 478.8m
Jian-Xun Li	VP, Deputy GM	6.7yrs	CN¥1.32m	0.0091% CN¥ 796.3k
Desi Pan	VP, Deputy GM	4.8yrs	CN¥1.21m	0.018% CN¥ 1.6m
Ou Hai	VP, Deputy GM	6.7yrs	CN¥1.02m	0.018% CN¥ 1.5m
Zhi-Bin Li	VP, Deputy GM and Head of Product Development & Production	no data	CN¥1.35m	0.0045% CN¥ 398.6k
Liangji She	VP, Deputy GM & Head of Oncology Division	no data	CN¥1.47m	0.0097% CN¥ 847.3k
Libin Zhang	VP, Deputy GM & Head of Metabolic Diseases Division	no data	CN¥1.36m	0.0098% CN¥ 861.3k
Leming Shi	Co-Founder	23.8yrs	Veri yok	Veri yok
Weiming Hu	Co-Founder	23.8yrs	Veri yok	Veri yok
Ji-Hui Yi	Vice President of Sales & Marketing	no data	Veri yok	Veri yok

15.3yrs

Ortalama Görev Süresi

53yo

Ortalama Yaş

Deneyimli Yönetim: 688321 'un yönetim ekibi deneyimli ve deneyimlidir ( 15.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Xian-Ping Lu	Founder	6.7yrs	CN¥3.38m	5.45% CN¥ 478.8m
Jian-Xun Li	VP, Deputy GM	6.7yrs	CN¥1.32m	0.0091% CN¥ 796.3k
Ou Hai	VP, Deputy GM	6.7yrs	CN¥1.02m	0.018% CN¥ 1.5m
Rui Lin Song	Independent Director	6.7yrs	CN¥150.00k	Veri yok
Xun Zhu	Independent Director	6.7yrs	CN¥150.00k	Veri yok
Hanpeng Yang	Director	no data	CN¥96.00k	Veri yok
Xiangyan Li	Independent Director	6.7yrs	CN¥150.00k	Veri yok
Zhengsheng Xie	Supervisor	3.7yrs	Veri yok	0.54% CN¥ 47.2m
Jingzhong Zhu	Employee Supervisor	4.9yrs	Veri yok	Veri yok
Jie He	Employee Supervisor	4.9yrs	Veri yok	Veri yok
Xia Jin	Employee Supervisor	3.7yrs	Veri yok	Veri yok
Weihua Li	Director	less than a year	Veri yok	Veri yok

6.7yrs

Ortalama Görev Süresi

50.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 688321 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.7 yıldır).

Shenzhen Chipscreen Biosciences Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Shenzhen Chipscreen Biosciences Co., Ltd., Annual General Meeting, Apr 19, 2024

Less than half of directors are independent

Recent updates

Shenzhen Chipscreen Biosciences Co., Ltd. announced that it expects to receive CNY 960 million in funding

Shenzhen Chipscreen Biosciences Co., Ltd. and Chengdu Chipscreen Pharmaceutical Ltd. Receives Drug Clinical Trial Approval Notice Approval Notice for Phase III Clinical Trials

New major risk - Financial position

Third quarter 2024 earnings released: CN¥0.025 loss per share (vs CN¥0.12 loss in 3Q 2023)

Shenzhen Chipscreen Biosciences Co., Ltd. Submits Investigational New Drug Application for CS231295 Tablets

Shenzhen Chipscreen Biosciences Co., Ltd.'s (SHSE:688321) 50% Price Boost Is Out Of Tune With Revenues

New minor risk - Share price stability

Shenzhen Chipscreen Biosciences Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

Shenzhen Chipscreen Biosciences Co., Ltd.'s (SHSE:688321) Price In Tune With Revenues

Shenzhen Chipscreen Biosciences Co., Ltd. to Report First Half, 2024 Results on Aug 16, 2024

We Think Shenzhen Chipscreen Biosciences (SHSE:688321) Has A Fair Chunk Of Debt

National Medical Products Administration Approves Chipscreen Biosciences Co., Ltd.'s Chidamide Combined with R-CHOP for the Treatment of Diffuse Large B-Cell Lymphoma

First quarter 2024 earnings released: CN¥0.045 loss per share (vs CN¥0.08 loss in 1Q 2023)

Investors Appear Satisfied With Shenzhen Chipscreen Biosciences Co., Ltd.'s (SHSE:688321) Prospects As Shares Rocket 26%

New major risk - Revenue and earnings growth

Solid Earnings May Not Tell The Whole Story For Shenzhen Chipscreen Biosciences (SHSE:688321)

Full year 2023 earnings: EPS and revenues miss analyst expectations

Shenzhen Chipscreen Biosciences Co., Ltd., Annual General Meeting, Apr 19, 2024

Shenzhen Chipscreen Biosciences Co., Ltd. to Report Q1, 2024 Results on Apr 29, 2024

Shenzhen Chipscreen Biosciences Co., Ltd. (SHSE:688321) commences an Equity Buyback Plan for CNY 15 million worth of its shares, under the authorization approved on February 22, 2024.

Shenzhen Chipscreen Biosciences Co., Ltd. Announces Positive Results from Phase II Clinical Trial (CGZ203 Study) of Chiglitazar Monotherapy for Non-Alalcoholic Steatohepatitis

Shenzhen Chipscreen Biosciences Co., Ltd.'s (SHSE:688321) Shares Climb 30% But Its Business Is Yet to Catch Up

Full year 2023 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorates as stock falls 24%

Third quarter 2023 earnings released: CN¥0.12 loss per share (vs CN¥0.056 loss in 3Q 2022)

New minor risk - Share price stability

Shenzhen Chipscreen Biosciences Co., Ltd. to Report First Half, 2023 Results on Aug 12, 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

Full year 2022 earnings released: EPS: CN¥0.043 (vs CN¥0.054 in FY 2021)

Now 20% undervalued

Less than half of directors are independent

Third quarter 2022 earnings released: CN¥0.056 loss per share (vs CN¥0.042 loss in 3Q 2021)

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Third quarter 2021 earnings released: CN¥0.042 loss per share (vs CN¥0.024 profit in 3Q 2020)

First quarter 2021 earnings released: CN¥0.018 loss per share (vs CN¥0.013 profit in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.076 (vs CN¥0.052 in FY 2019)

Shenzhen Chipscreen Biosciences Co., Ltd. Announces Voluntary Disclosure of Application for Clinical Trial Accepted

Full year 2020 earnings released: EPS CN¥0.076 (vs CN¥0.052 in FY 2019)

Revenue beats expectations, earnings disappoint

New 90-day low: CN¥33.79

Shenzhen Chipscreen Biosciences Co., Ltd. Submits Its Pivotal Phase III Clinical Trial Application of National Class I Innovative Drug Chiauranib

New 90-day low: CN¥36.33

Shenzhen Chipscreen Biosciences Co., Ltd. Announces CDE "Breakthrough Therapy Designation"

New 90-day low: CN¥39.35

CHIPSCREEN and HISUN Reach A Strategic Cooperation

New 90-day low: CN¥44.13

New 90-day low: CN¥45.51

New 90-day low - CN¥49.02

First half earnings released

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş